Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigen recognition and T-cell biology.

Michael I Nishimura1, Jeffrey J Roszkowski, Tamson V Moore

  • 1Department of Surgery, University of Chicago Medical Center, Chicago, IL 60637, USA.

Cancer Treatment and Research
|October 11, 2005
PubMed
Summary

Cancer patients possess tumor-reactive T cells, but immune therapy often fails due to T cell signaling defects. Enhancing T cell function alongside immunotherapy may improve cancer treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.

The Journal of clinical investigation·2026
Same author

H<sub>2</sub>S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response.

Science advances·2024
Same author

Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR.

Molecular therapy. Methods & clinical development·2024
Same author

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.

Journal for immunotherapy of cancer·2024
Same author

CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary Angioedema.

The New England journal of medicine·2024
Same author

Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.

Blood advances·2023

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • T cells are crucial for recognizing cancer cells.
  • Many cancer patients have T cells that can target their tumors.
  • Current cancer immunotherapies face challenges in achieving widespread clinical responses.

Purpose of the Study:

  • To explore the reasons behind the limited success of T cell-based cancer immunotherapies.
  • To identify potential strategies for improving the efficacy of cancer immune treatments.
  • To highlight the promise of T cell-mediated cancer therapy.

Main Methods:

  • Review of existing knowledge on T cell recognition of tumor targets.
  • Analysis of T cell repertoire and function in cancer patients.
  • Examination of clinical responses to current immunotherapies.

Related Experiment Videos

Main Results:

  • Most cancer patients have T cells capable of recognizing tumor cells.
  • Despite the presence of tumor-reactive T cells, patients often progress.
  • Defects in T cell signaling are a potential cause for treatment failure.
  • Periodic objective clinical responses indicate that immunotherapy can be effective.

Conclusions:

  • Cancer patients have the inherent capacity to mount immune responses against their tumors.
  • Modulating T cell function is critical for successful cancer immunotherapy.
  • Combining agents that alter T cell function with vaccination or adoptive T cell transfer shows promise for effective cancer treatment.